Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder

European Neuropsychopharmacology

Volumn 18, Issue 12, 2008, Pages 917-924

  Hernández, María Eugenia ^a,b   Mendieta, Danelia ^a   Martínez Fong, Daniel ^c   Loría, Frida ^a   Moreno, Julia ^a   Estrada, Iris ^d   Bojalil, Rafael ^e   Pavón, Lenin ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^e INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Cortisol; Cytokines; HDRS; HPA axis; MDD; SSRI

Indexed keywords

CYTOKINE; ESCITALOPRAM; FLUOXETINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REMISSION;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROCORTISONE; LONGITUDINAL STUDIES; MALE; PSYCHIATRIC STATUS RATING SCALES; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; YOUNG ADULT;

EID: 53649099619     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.08.001     Document Type: Article

References (53)

1. Ader R., Felten D.L., and Cohen N. Psychoneuroimmunology (2001) Academic Press, San Diego California, USA
2. Aihara M., Ida I., Yuuki N., Oshima A., Kumano H., Takahashi K., Fukuda M., Oriuchi N., Endo K., Matsuda H., and Mikuni M. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res. 155 (2007) 245-256
3. Antonijevic I.A. Depressive disorders - is it time to endorse different pathophysiologies?. Psychoneuroendocrinology 31 (2006) 1-15
4. Axelson D.A., Doraiswamy P.M., McDonald W.M., Boyko O.B., Tupler L.A., Patterson L.J., Nemeroff C.B., Ellinwood Jr. E.H., and Krishnan K.R. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 47 (1993) 163-173
5. Basterzi A.D., Aydemir C., Kisa C., Aksaray S., Tuzer V., Yazici K., and Goka E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20 (2005) 473-476
6. Beck A.T., Steer R.A., Beck J.S., and Newman C.F. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life-Threat. Behav. 23 (1993) 139-145
7. Bhagwagar Z., Whale R., and Cowen P.J. State and trait abnormalities in serotonin function in major depression. Br. J. Psychiatry 180 (2002) 24-28
8. Blardi P., De Lalla A., Leo A., Auteri A., Iapichino S., Di M.A., Dell'Erba A., and Castrogiovanni P. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J. Clin. Psychopharmacol. 22 (2002) 131-136
9. Castrogiovanni P., Blardi P., De Lalla A., Dell'Erba A., and Auteri A. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?. Psychopharmacol. Bull. 37 (2003) 102-108
10. Cleare A.J. Reduced whole blood serotonin in major depression. Depress. Anxiety 5 (1997) 108-111
11. Cohen S., Janicki-Deverts D., and Miller G.E. Psychological stress and disease. JAMA 298 (2007) 1685-1687
12. De Kloet E.R., Derijk R.H., and Meijer O.C. Therapy insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression?. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 168-179
13. Diamond M., Kelly J.P., and Connor T.J. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 16 (2006) 481-490
14. Elenkov I.J. Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci. 1024 (2004) 138-146
15. Farber L., Haus U., Spath M., and Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand. J. Rheumatol., Suppl. (2004) 2-8
16. Gonzalez A., Fazzino F., Castillo M., Mata S., and Lima L. Serotonin, 5-HT1A serotonin receptors and proliferation of lymphocytes in major depression patients. Neuroimmunomodulation 14 (2007) 8-15
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
18. Heinze G. M.I.N.I. 5.0.0 .Mini International Neuropsychiatric Interview. [Spanish South and Central America version/DSM-IV] (2000) Sheehan DV and Lecubrier Y
19. Hiscock N., Chan M.H., Bisucci T., Darby I.A., and Febbraio M.A. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 18 (2004) 992-994
20. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
21. Huber T.J., Issa K., Schik G., and Wolf O.T. The cortisol awakening response is blunted in psychotherapy inpatients suffering from depression. Psychoneuroendocrinology 31 (2006) 900-904
22. Johnson D.A., Grant E.J., Ingram C.D., and Gartside S.E. Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant. Biol. Psychiatry 62 (2007) 1228-1235
23. Keller P., Penkowa M., Keller C., Steensberg A., Fischer C.P., Giralt M., Hidalgo J., and Pedersen B.K. Interleukin-6 receptor expression in contracting human skeletal muscle: regulating role of IL-6. FASEB J. 19 (2005) 1181-1183
24. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol., Endocrinol. Metab. 280 (2001) E745-E751
25. Kronfol Z., and Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 157 (2000) 683-694
26. Kubera M., Maes M., Kenis G., Kim Y.K., and Lason W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 134 (2005) 251-258
27. Kupfer D.J. Long-term treatment of depression. J. Clin. Psychiatry 52 Suppl (1991) 28-34
28. Legros S., Mendlewicz J., and Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur. Arch. Psychiatr. Neurol. Sci. 235 1 (1985) 9-11
29. Leo R., Di L.G., Tesauro M., Razzini C., Forleo G.B., Chiricolo G., Cola C., Zanasi M., Troisi A., Siracusano A., Lauro R., and Romeo F. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J. Clin. Psychiatry 67 (2006) 1760-1766
30. Leonard B.E. Psychopathology of depression. Drugs Today (Barc.) 43 (2007) 705-716
31. Lima L., and Urbina M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell. Mol. Neurobiol. 22 (2002) 797-804
32. Loftis J.M., and Hausser P. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 82 (2004) 175-190
33. Lopez J.F., Chalmers D.T., Little K.Y., and Watson S.J. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 43 (1998) 547-573
34. Maes M., Kenis G., Kubera M., De B.M., Steinbusch H., and Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int. Immunopharmacol. 5 (2005) 609-618
35. Meltzer H., Bastani B., Jayathilake K., and Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 17 (1997) 1-11
36. Mossner R., and Lesch K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 12 (1998) 249-271
37. Nichols J.H., Charlson J.R., and Lawson G.M. Automated HPLC assay of fluoxetine and norfluoxetine in serum. Clin. Chem. 40 (1994) 1312-1316
38. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., and Mathe A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 8 (2005) 403-410
39. Nikisch G., Mathe A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., and Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) 181 (2005) 751-760
40. Okuyama-Tamura M., Mikuni M., and Kojima I. Modulation of the human glucocorticoid receptor function by antidepressive compounds. Neurosci. Lett. 342 (2003) 206-210
41. Papiol S., Arias B., Gasto C., Gutierrez B., Catalan R., and Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. 104 (2007) 83-90
42. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
43. Paul E.W. Fundamental Immunology (2003) Lippincott Williams & Wilkins, Philadelphia
44. Pavon L., Sandoval-Lopez G., Eugenia H.M., Loria F., Estrada I., Perez M., Moreno J., Avila U., Leff P., Anton B., and Heinze G. Th2 cytokine response in major depressive disorder patients before treatment. J. Neuroimmunol. 172 (2006) 156-165
45. Rook G.A. Glucocorticoids and immune function. Bailliere's Best Pract. Res. Clin. Endocrinol. Metab. 13 (1999) 567-581
46. Sapolsky R.M., and Plotsky P.M. Hypercortisolism and its possible neural bases. Biol. Psychiatry 27 (1990) 937-952
47. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 29 (2005) 201-217
48. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev., Immunol. 6 (2006) 318-328
49. Thakore J.H., Barnes C., Joyce J., Medbak S., and Dinan T.G. Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res. 73 (1997) 27-32
50. Tracey K.J. The inflammatory reflex. Nature 420 (2002) 853-859
51. Tsao C.W., Lin Y.S., Chen C.C., Bai C.H., and Wu S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 (2006) 899-905
52. Vythilingam M., Vermetten E., Anderson G.M., Luckenbaugh D., Anderson E.R., Snow J., Staib L.H., Charney D.S., and Bremner J.D. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol. Psychiatry 56 (2004) 101-112
53. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., and Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15 (2001) 199-226